Canada markets closed

Lucid Diagnostics Inc. (LUCD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.6100-0.0700 (-4.17%)
At close: 04:00PM EDT
1.6330 +0.02 (+1.43%)
After hours: 05:41PM EDT

Lucid Diagnostics Inc.

One Grand Central Place
Suite 4600
New York, NY 10165
United States
212 949 4319

IndustryMedical Devices
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Lishan Aklog M.D.Chairman & CEON/AN/A1966
Mr. Dennis M. McGrath CPACFO, Pres & Sec.N/AN/A1957
Dr. Sanford D. Markowitz M.D., Ph.D.Cofounder & Strategic Advisor, Member of the Medical Advisor Board14.54kN/AN/A
Dr. Joseph Willis M.D.Cofounder, Strategic Advisor & Member of Medical Advisory BoardN/AN/AN/A
Dr. Amitabh Chak M.D.Cofounder, Strategic Advisor & Member of Medical Advisory BoardN/AN/AN/A
Mr. Shaun M. O'Neill M.B.A.Exec. VP & COON/AN/A1982
Richard D. YazbeckChief Technology OfficerN/AN/AN/A
Dr. Suman M. Verma M.D., Ph.D.Chief Scientific OfficerN/AN/AN/A
Dr. Brian J. deGuzman M.D.Chief Compliance OfficerN/AN/A1965
Michael ParksVP of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Corporate Governance

Lucid Diagnostics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.